Current Edition

Current features

Transparent, Pret-a-porter Operations Quality Measurement & Other 2024 Priorities for Drug Manufacturers & the Supply Chain

In Life Sciences manufacturing quality and compliance, the global digitalisation drive continues a-pace as the pressure builds to innovate, collaborate and contain c...
Continue Reading →
Current features

Diabesity: Implications for Treatment and Drug Development

The term “diabesity” has been used to refer to the twin pandemics of type 2 diabetes (T2D) and obesity.1 It was originally used after experiments showed that overfee...
Continue Reading →
Current features

Developing Effective Supply Chain Strategies Utilising Forecasting Technology

Drug development has evolved considerably over recent decades, along with the clinical supply chains that underpin the continued advancement of human health. In t...
Continue Reading →
Regional News

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of fun...
Continue Reading →
Regional News

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS...
Continue Reading →
Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...
Continue Reading →
Regional News

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and...
Continue Reading →
Regional News

After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspaveli

After rare disease drugmaker Sobi reportedly had a buyout scuppered by pharma giant AstraZeneca, the company has picked up a win that stands to bolster its Aspaveli l...
Continue Reading →
Europe

PROSTATE CANCER DRUG BYPRODUCT CAN FUEL CANCER CELLS, UNITED STATES-BASED RESEARCHERS FIND

A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research in the United Sta...
Continue Reading →
Europe

Speeding Drug Development with Clinical Trials in a Dish

The average time to bring a new drug to market is 12 years—assuming it makes it through the rigorous regulatory hurdles. Any technology or methodology that can exped...
Continue Reading →